Opinion

Video

Second-Line LR- MDS Setting: Treatment Options and Considerations

Panelists discuss how they determine thresholds for changing therapy in patients with MDS, evaluate second-line treatment options including the potential use of ESAs after luspatercept, and offer key takeaways for community colleagues managing similar clinical scenarios.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • What is your threshold for changing therapy in your clinical practice?
    • What treatment options would you consider in the second-line setting for this patient? Do you consider trialing ESAs post luspatercept?
    • What are some key takeaways you can offer community colleagues from this clinical scenario and discussion?

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data

    Related Content